Non-osseous incidental findings in low-dose whole-body CT in patients with multiple myeloma

Objective:

The purpose of this study was to identify the frequency and grading of non-osseous incidental findings (NOIF) in non-contrast whole-body low-dose CT (LDCT) in patients with multiple myeloma.

Methods:

In the time period from 2010 to 2013, 93 patients with multiple myeloma were staged by non-contrast whole-body LDCT at our radiological department. LDCT images were analysed retrospectively for NOIF, which also included unsuspected extramedullary manifestation of multiple myeloma. All NOIF were classified as major or clinically significant, moderate or possibly clinically significant and minor or not clinically significant. Medical records were analysed regarding further investigation and follow-up of the identified NOIF.

Results:

In the 93 patients, 295 NOIF were identified (on average, 3.2 NOIF per patient). Most of the NOIF (52.4%) were not clinically significant, 25.8% of the NOIF were possibly clinically significant and 21.8% of the NOIF were clinically significant. Clinically significant NOIF were investigated further by CT after intravenous administration of contrast medium and/or by ultrasound or MRI. In 34 of these cases, extramedullary relapse of myeloma, occult carcinoma or infectious/septic incidental findings were diagnosed (11.5% of all NOIF). In the remaining 10.3% of the NOIF classified as clinically significant, various benign lesions were diagnosed.

Conclusion:

LDCT detected various non-osseous lesions in patients with multiple myeloma. 36.6% of the patients had clinically significant NOIF. Therefore, LDCT examinations in patients with multiple myeloma should be evaluated carefully for the presence of NOIF.

Advances in knowledge:

LDCT identified several NOIF. A total of 36.6% of patients with multiple myeloma had clinically significant NOIF. Radiologists should analyse LDCT examinations in patients with multiple myeloma not only for bone lesions, but also for lesions in other organs.CT is used for screening or staging in several malignancies.^1–8 As reported previously, the staging CT examination also provides additional information regarding the general health status of the patient or so-called incidental findings (IF).^1,3,6,7 Several IF on CT examinations were described in the literature.^1–6 According to previous reports, IF can be classified into five different categories: Group “0”, limited examination, that is, evaluation of IF are severely limited; Group “1”, normal findings or anatomic variant; Group “2”, clinically unimportant findings, such as liver or kidney cysts; Group “3”, likely unimportant findings; and Group “4”, potentially important findings, such as solid renal masses or lymphadenopathy.⁵ In another publication, a three-part classification of IF according to their clinical importance was proposed, namely major, moderate and minor IF.¹Most of the IF are clinically non-significant, such as colonic diverticula or simple cysts.^1–7 However, serious IF, such as aortic aneurysm or dissection, thrombosis, pulmonary embolism and second primary tumours, can also occur,^1,3,6,7 and some of them may be not visible on low-dose CT (LDCT).Most reports regarding IF are based on contrast-enhanced CT.^1,7,9–11 There are only a few reports regarding IF in LDCT.¹² They described IF in screening programmes for lung cancer and based the findings on thoracic LDCT only.¹² In addition, non-contrast LDCT has been established for staging of bone lesions in multiple myeloma.^13–16 However, radiologists should analyse LDCT examinations not only for bone lesions but also for lesions in other organs, which may include extramedullary manifestation of multiple myeloma as well as unrelated IF.Although IF in multiple myeloma have also been described previously,¹⁴ to the best of our knowledge, there exists no analysis focused on frequency and distribution of non-osseous IF (NOIF) on whole-body LDCT. Therefore, the purpose of this study was to identify the frequency and grading of NOIF in non-contrast whole-body LDCT in patients with multiple myeloma.